Novalgine (Metamizole Sodium)

Metamizole sodium is believed to inhibit cyclo‑oxygenase enzymes, decreasing prostaglandin production, and to act on central pain pathways in the spinal cord and brain. This combined effect provides analgesic and antipyretic benefits, although the exact molecular mechanisms are not fully clarified.

The appropriate dose of Novalgine is determined by the prescribing clinician based on the patient’s age, weight, severity of pain or fever, and overall health status. Dosage regimens can vary, and the prescriber will provide specific instructions.

Safety data for metamizole sodium in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with traditional NSAIDs, metamizole sodium offers strong analgesic and antipyretic effects with a lower risk of gastrointestinal irritation. However, it carries a rare but serious risk of agranulocytosis, which is not typical for many NSAIDs, so risk‑benefit assessment is essential.

Novalgine should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid storing in humid environments.

Novalgine is administered orally, usually in tablet or oral liquid form, as directed by the prescriber. It should be taken with or without food according to the clinician’s guidance, and the full prescribed course should be completed unless advised otherwise.

The most serious adverse effect is agranulocytosis, a potentially life‑threatening reduction in white‑blood‑cell count. Other severe risks include anaphylactic reactions, severe skin reactions, and significant liver or kidney impairment. Prompt medical attention is required if any serious symptoms develop.

Novalgine should be avoided in individuals with known hypersensitivity to metamizole or other pyrazolone derivatives, in patients with existing severe blood dyscrasias, and in those taking other myelosuppressive drugs without close monitoring. Clinicians should also exercise caution in patients with compromised liver or kidney function.